Long-term treatment with GTS-21 or nicotine enhances water maze performance in aged rats without affecting the density of nicotinic receptor subtypes in neocortex

Drug Development Research

Volumn 39, Issue 1, 1996, Pages 19-28

  Bjugstad, Kimberly B ^a   Mahnir, Vladimir M ^b   Kem, William R ^b   Socci, Debra J ^a   Arendash, Gary W ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Hippocampus; Learning memory; Neostriatum

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE;

AGED; AGING; ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BINDING SITE; BRAIN REGION; COGNITION; CONTROLLED STUDY; HISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; MEMORY CONSOLIDATION; NEOCORTEX; NEOSTRIATUM; NEUROCHEMISTRY; NEUROMUSCULAR SYNAPSE; NONHUMAN; RAT; RECEPTOR DENSITY;

EID: 0030482929     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(19960901)39:1<19::AID-DDR3>3.0.CO;2-N     Document Type: Article

References (51)

1. Arendash GW, Sanberg PR, Senstock GJ (1995a): Nicotine enhances the learning and memory of aged rats. Pharmacol Biochem Behav 52:517-523.
2. Arendash GW, Sengstock CJ, Sanberg PR, Kern WR (1995b): Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist, GTS-21. Brain Res 674:252-259.
3. Arimatsu Y, Akiko S, Amano T (1981): An atlas of a-bungarotoxin binding sites and structures containing acetylcholinesterase in the mouse central nervous system. J Comp Neurol 198:630-631.
4. Arneric S, Sullivan J, Briggs C, Donnelly-Roberts D, Anderson D, Raszkiewicz J, Hughes M, Cadman E, Adams P, Garvey D, Wasicak J, Williams M (1994): ABT-418: A novel cholinergic ligand with cognition enhancing and anxiolytic activities. I. In vitro characterization. J Pharmacol Exp Ther 270:310-318.
5. Benowitz NL (1986): Clinical pharmacology of nicotine. Annu Rev Med 37:21-32.
6. 3H]nicotine binding sites in human brain. J Neurochem 50:1243-1247.
7. Brandeis R, Brandys Y, Yehuda S (1989): The use of the Morris water maze in the study of memory and learning. Int J Neurosci 48:29-26.
8. Britto LR, Hamassaki-Britto DE, Ferro ES, Keyser KT, Karten HJ, Lindstrom JM (1992): Neurons in the chick brain and retina expressing both alpha-bungarotoxin-sensitive and alpha-bungarotoxin-insensitive nicotinic acetylcholine receptors: An immuno-histochemical analysis. Brain Res 590:193-200.
9. I25I]α-bungarotoxin. J Neurosci 5:1307-1315.
10. Davis S, Markowsa AL, Wenk GL, Barnes CA (1993): Acetyl-Lcarnitine: Behavioral, electrophysiological, and neurochemical effects. Neurobiol Aging 14:107-115.
11. 125I-alpha-bungarotoxin receptor subtypes. Mol Pharmacol 47:164-171.
12. Decker M, Brioni J, Sullivan J, Buckley M, Radek R, Raszkiewicz J, Kang C, Kim D, Giardina W, Waicak J, Garvey D, Williams M, Arneric S (1994a); (S)-3-Methyl-5-(methyl-2-pyrrolidinyl)isoxazole (ABT-418): A novel cholinergic ligand with cognitionenhancing and anxiolytic activities. II. In vivo characterization. J Pharm Exp Therapuetics 270: 319-328.
13. Decker M, Curzon P, Brioni J, Arneric S (1994b): Effects of ABT418, a novel cholinergic channel ligand on place learning in septal-lesioned rats. European J Pharmacol 261:217-222.
14. Engstrom DA, Bickford P, De La Garza R, Young D, Rose GM (1993): Increased responsiveness of hippocampal pyramidal neurons to nicotine in aged, learning-impaired rats. Neurobiol Aging 14:259-266.
15. Flores CM, Rogers SW, Pabraze LA, Wolfe BB, Kellar KJ (1992): A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41:31-37.
16. Hunter WM, Greenwood FC (1970): Preparation of Iodine-131 labeled human growth hormone of high specific activity. Nature 194:495-496.
17. Hunter BE, de Fiebre CM, Papke RL, Kem WR, Meyer EM (1994): A novel nicotinic agonist facilitates induction of long term potentiation in rat hippocampus. Neurosci Lett 168:130-134.
18. Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992): Effects of acute subcutaneous nicotine on attention information processing and short term memory in Alzheimer's disease. Psychopharmacology 108:485-494.
19. Kem WR (1971): A study of the occurrence of anabaseine in Paranemertes and other nemertines. Toxicon 9:23-32.
20. Kem WR, Abbott BC, Coates RM (1971): Isolation and structure of a hoplonemertine toxin. Toxicon 9:15-22.
21. Kem WR, Mahnir VM, Lin B (1994): Interaction of DMXB (GTS21), a cognition-enhancing compound with cholinergic receptors. Soc Neurosci Abs 20:1134.
22. Levin ED (1992): Nicotinic systems in cognitive function. Psychopharmacology 108:417-431.
23. Luetje CW, Wada K, Rogers S, Abramsom SN, Tsuji K, Heine. mann S, Patrick J (1990): Neurotoxins distinguish between different neuronal nicotinic acetylcholine receptor subunit combinations J Neurochem 55: 632-640.
24. Maelicke A, Albuquerque E (1996): New approach to drug therapy in Alzheimers dementia. Drug Dev Technol 1:53-59.
25. Marchand CMF, Hunt SP, Schmidt J (1979): Putative acetylcholine receptors in hippocampus and corpus striatum of rat and mouse. Brain Res 160:363-367.
26. Marks MJ, Burch JB, Collins AC (1983): Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther 226:817-825.
27. Marks MJ, Stitzel JA, Collins AC (1985): Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther 235:619-628.
28. Marks MJ, Stitzel JA, Romm E, Wehner JM, Collins AC (1986): Nicotinic binding sites in rat and mouse brain: Comparison of acetylcholine, nicotine, and α-bungarotoxin. Mol Pharmacol 30: 427-436.
29. Mellon RD, Houghtling RA, Kellar KJ (1994): Increase in neuronal nicotinic receptor binding sites following chronic cytisine treatment. Soc Neurosci Abs 20:1136.
30. Meyer EM, De Fiebre CM, Hunter BE, Simpkins CE, Frauworth N, De Fiebre NEC (1994): Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors. Drug Dev Res 31:127-134.
31. Morley BJ, Lorden JF, Brown GB, Kemp GE, Bradley RJ (1977): Regional distribution of nicotinic acetylcholine receptor in rat brain. Brain Res 134:161-166.
32. Mundy WR, Iwamoto ET (1988a): Actions of nicotine on the acquisition of an autoshaped lever-touch response in rats. Psychopharmacology 94:267-274.
33. Mundy WR, Iwamoto ET (1988b): Nicotine impairs acquisition of radial maze performance in rats. Pharmacol Biochem Behav 30: 119-122.
34. Newhouse PA, Potter A, Lenox R (1993): The effects of nicotinic agents on human cognition: Possible therapeutic applications in Alzheimers and Parkinson's diseases. Med Chem Res 2:628642.
35. Olton DS, Papas BC (1979): Spatial memory and hippocampal function. Neuropsychologia 17:669-682.
36. Papke RL, de Fiebre CM, Kern WR, Meyer EM (1994): The subunit specific effects of novel anabaseine-derived nicotinic agents. Proceedingsof the Third International Springfield Symposium on Advances in Alzheimer Therapy (in press).
37. Petri HL, Mishkin M (1994); Behaviorism, cognitivism, and the neuropsychology of memory. Am Sci 82:30-37.
38. Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, LeNovere N, Vincent P, Pich EM, Brulet P, Changeux JP (1995): Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 374:65-67.
39. Porsolt RD (1989): The silent epidemic: The search for treatment of age-related memory impairment. Trends Pharmacol Sei 10: 3-6.
40. Prabeza LA, Subhash D, Kellar KJ (1990): [3H]cytisine binding to nicotinic cholinergic receptors in the brain. Mol Pharmacol 39: 9-12.
41. Rapp PR, Rosenberg RA, Gallagher M (1987): An evaluation of spatial information processing in aged rats. Behav Neurosci 101: 3-12.
42. Sahakian B, Jones G, Levy R, Gray J, Warburton D (1989): The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of Alzheimer's type. Br J Psychiatry 154:797-800.
43. Schaefer GJ, Michael RP (1986): Task-specific effects of nicotine in rats: Intracranial self stimulation and locomotor activity. Neuropharmacology 25: 125-131.
44. Schwartz RD, Kellar KJ (1983): Nicotinic cholinergic receptor binding sites in the brain: Regulation in vivo. Science 220:214-216.
45. 3H]acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J Neurochem 45:427-433.
46. Segal M, Dudai Y, Amsterdam A (1978): Distribution of an a-bungarotoxin-binding cholinergic nicotinic receptor in rat brain. Brain Res 148:105-119.
47. Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW (1993): Molecular cloning, functional properties, and distribution of rat brain α7: A nicotinic cation channel highly permeable to calcium. J Neurosci 13:596-604.
48. Socci DJ, Sanberg PR, Arendash GW (1995): Nicotine enhances Morris water maze performance of young and aged rats. Neurobiol Aging 16:857-860.
49. Warburton DM (1992): Nicotine as a cognitive enhancer. Progressive Neuropsychopharmacol Biol Psychiatry 16:181-191.
50. Woodruff-Pak DS, Yong-Tong L, Kern WR (1994): A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res 645:309-317.
51. Zhang WQ, Mundy WR, Thai L, Hudson PM, Gallagher M, Tilson HA, Hong JS (1991): Decreased glutamate release correlates with elevated dynorphin content in the hippocampus of aged rats with spatial learning deficits. Hippocampus 1:391-397.